Study to Evaluate Adverse Events and Movement of Lemzoparlimab in Body When Used Intravenously (IV) With Azacitidine Subcutaneously or IV and Venetoclax Orally in Participants With Acute Myeloid Leukemia and With Azacitidine With or Without Venetoclax in Participants With Myelodysplastic Syndrome

TERMINATED

Identifier: CI-TRIAL-00074376
Entity page: /trial/NCT04912063 ↗
Edges: 4

Neighbours: 2 cancers2 drugs
Drawn: 4 of 4 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,147 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Study to Evaluate Adverse Events and Movement of Lemzoparlimab in Body When Used Intravenously (IV) With Azacitidine Subcutaneously or IV and Venetoclax Orally in Participants With Acute Myeloid Leukemia and With Azacitidine With or Without Venetoclax in Participants With Myelodysplastic Syndrome condition of …CONDITION_OFderived2 of 2
← condition of	Acute Myeloid Leukemia registry condition “Acute Myeloid Leukemia (AML)” mapped CURATED_BROADER	—	—	Acute Myeloid Leukemia	1	Observed	clinicaltrials	graph →
← condition of	Myelodysplastic Syndrome

Study to Evaluate Adverse Events and Movement of Lemzoparlimab in Body When Used Intravenously (IV) With Azacitidine Subcutaneously or IV and Venetoclax Orally in Participants With Acute Myeloid Leukemia and With Azacitidine With or Without Venetoclax in Participants With Myelodysplastic Syndrome intervention of …INTERVENTION_OFderived2 of 2
← intervention of	Azacitidinesmall molecule registry intervention “Azacitidine” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Venetoclaxsmall molecule registry intervention “Venetoclax” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →

Study to Evaluate Adverse Events and Movement of Lemzoparlimab in Body When Used Intravenously (IV) With Azacitidine Subcutaneously or IV and Venetoclax Orally in Participants With Acute Myeloid Leukemia and With Azacitidine With or Without Venetoclax in Participants With Myelodysplastic Syndrome intervention of …INTERVENTION_OFderived2 of 2

← intervention of

Azacitidinesmall molecule

registry intervention “Azacitidine” (DRUG) mapped ALIAS

—

not mapped

Observed

clinicaltrials

graph →